anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
In the SAD part of the study the investigational drug will be administered once in a dose escalation manner starting from 200 mg in Cohort 1 to 2000 mg in Cohort 6. The study drug will be orally taken as capsules. In the MAD part of the study the investigational drug will be administrated twice daily for 5 days depending on the half-life of FP-025, as determined in the SAD part of the study. Study subjects will be randomized in a 1:3 ratio to either placebo or FP-025 in every cohort of the SAD and MAD part of the study.

Note: Dosing in the SAD phase was completed, and the planned MAD portion of the study was not conducted. Evaluation of FP-025 MAD is being conducted under a separate protocol (Study No. FP02C-17-001).
<P>PROBLEM TO BE SOLVED: To provide a medicine comprising IGF-I (insulin-like growth factor-I) administered in a fashion such that the maximum favorable biological activity of IGF-I is achieved and maintained in the treatment of chronic disorders with minimized unfavorable side effects for the treatment of the chronic disorders (e.g. renal failure or diabetes) in the mammal.  <P>SOLUTION: There is provided the medicine comprising IGF-I administered in the fashion as follows: IGF-I is administered to provide an exposure to the mammal over a period of time during which the maximum biological response is generated. The administration is then discontinued for a period of time equal to or less than the period of time during which the IGF-I was previously administered, and the IGF-I is subsequently administered to provide the exposure to the mammal over a period of time that provides the maximum biological response. The administration is then discontinued for a period of time equal to or less than the period of time during which the IGF-I was just previously administered, and the pattern of the administration and discontinuance of the administration is repeated over a period of time necessary to achieve or maintain the sustained biological response in the mammal.  <P>COPYRIGHT: (C)2009,JPO&INPIT
In this study, a priori power analysis was performed before starting the study to determine the sample size. In the power analysis, it was determined that the number of samples should be 80, 40 interventional and 40 control, with a 0.05 significance level, 95% confidence interval, 95% power and a 5% margin of error.

SPSS 23.0 (Statistical Program for Social Sciences) package program will be used to evaluate the data obtained from the research. The suitability of variables to normal distribution will be examined visually (histograms, probability plots) and analytical methods (Kolmogorov-Smirnov test). When comparing control and intervention groups, independent groups t-test will be used for comparisons between normally distributed continuous variables, and chi-square test will be used for categorical variables. Comparing the scale scores before and after the application in the intervention group, if the data shows a normal distribution, paired t test will be applied, if it does not show a normal distribution, the Wilcoxon test will be applied. The relationships between variables will be evaluated using Pearson correlation analysis for normally distributed values, and Spearman correlation analysis for non-normally distributed values. Statistical significance level will be accepted as p\<0.05
The invention discloses a cell line for preparing a Col17-IgG1Fc fusion protein and application thereof. The invention provides a 293T cell line BPKU in stable transfection by COL17NC16A-IgG1Fc plasmids, and the cell line has a preservation number of CGMCCNo.7801. The invention also protects the application of BPKU to preparation of Col17-IgG1Fc fusion protein, application of Col17-IgG1Fc fusion protein to preparation of drugs for the treatment of bullous pemphigoid. The existing drug rituximab for the treatment of bullous pemphigoid has the killing effect on all B cells and causes severe side effect. However, the Col17-IgG1Fc fusion protein has specific killing effect on COL17NC16A specific B cells in the patients with bullous pemphigoid function, can avoid killing other B cells, and has extremely low side effect. The cell line BPKU provided by the invention has the performance of high efficiency production of Col17NC16A-IgG1Fc fusion protein. The invention has great value to the treatment of bullous pemphigoid.
Of the 229 patients in the randomized study who received ABRAXANE for the treatment of metastatic breast cancer, 13% were at least 65 years of age and < 2% were 75 years or older. This study of ABRAXANE did not include a sufficient number of patients with metastatic breast cancer who were 65 years and older to determine whether they respond differently from younger patients.

A subsequent pooled analysis was conducted in 981 patients receiving ABRAXANE monotherapy for metastatic breast cancer, of which 15% were 65 years of age or older and 2% were 75 years of age or older. A higher incidence of epistaxis, diarrhea, dehydration, fatigue, and peripheral edema was found in patients 65 years of age or older.

Of the 514 patients in the randomized study who received ABRAXANE and carboplatin for the first-line treatment of non-small cell lung cancer, 31% were 65 years or older and 3.5% were 75 years or older. Myelosuppression, peripheral neuropathy, and arthralgia were more frequent in patients 65 years or older compared to patients younger than 65 years old. No overall difference in effectiveness, as measured by response rates, was observed between patients 65 years or older compared to patients younger than 65 years old. 

Of the 431 patients in the randomized study who received ABRAXANE and gemcitabine for the first-line treatment of pancreatic adenocarcinoma, 41% were 65 years or older and 10% were 75 years or older. No overall differences in effectiveness were observed between patients who were 65 years of age or older and younger patients. Diarrhea, decreased appetite, dehydration, and epistaxis were more frequent in patients 65 years or older compared with patients younger than 65 years old. Clinical studies of ABRAXANE did not include sufficient number of patients with pancreatic cancer who were 75 years and older to determine whether they respond differently from younger patients.
A cosmetic cleansing agent containing (i) 1-50% wt, preferably 2-10%, of a biosurfactant, (ii) 0.5-30% wt, preferably 1-20%, of an anionic surfactant and (iii) 0.1-40% wt, preferably 1-10%, of a thickener, and also containing less than 0.1 wt.%, preferably being entirely free of, polyethylene glycol, polypropylene glycol, ethylene oxide-containing compounds and propylene oxide-containing compounds. The biosurfactant may be a glycolipid preferably selected from rhamnolipids, sophorolipids or mannosylerythritol lipids a lipopeptide preferably selected from surfactins, fatty acyl glutamates or fatty acyl glycinates or a combination thereof. A sophorolipid in the form of a mixture of 20-60% acid and 40-80% lactone, or a mono- / dirhamnolipid mixture derived from 3-hydroxydodecanoic acid and 3-hydroxyundecanoic acid are particularly preferred. The anionic surfactant may be selected from linear alkane sulphates, monoalkyl / dialkyl sulfosuccinates, acyl isethionates, acyl sarcosines, acyl glutamates and/or acyl glycinates. The thickener may be xanthan gum, guar gum, gellan gum, sorbitan sesquicaprylate, glyceryl laurate, glyceryl caprylate and/or glyceryl caprate, preferably xanthan gum and/or sorbitan sesquicaprylate. The cosmetic cleanser is preferably formulated as a shampoo or shower gel.
The invention discloses an antibody pair specific to MMP-9, a biological material and application thereof, belonging to the field of biomedicine. The antibody pair comprises a first antibody chrysM 22 and a second antibody chrysM 37, wherein CDRs of complementarity determining regions of a heavy chain H22 and a light chain K22 of the first antibody chrysM 22 are shown in SEQ ID NO. 01-06; the CDRs of the complementarity determining regions of the heavy chain H37 and the light chain K37 of the second antibody chrM37 are shown in SEQ ID NO. 07-12. The novel anti-MMP-9 antibody pair can realize efficient recognition and inhibition of MMP-9 and provide a novel means for detection and treatment of diseases. By introducing highly specific antibody pairs, it is expected that the activity of MMP-9 can be accurately identified and regulated at the molecular level, providing a more effective and safer solution for disease treatment and patient health.
OBJECTIVE: This study aims to construct and evaluate a model to predict spontaneous vaginal delivery (SVD) failure in term nulliparous women based on machine learning algorithms.
METHODS: In this retrospective observational study, data on nulliparous women without contraindications for vaginal delivery with a singleton pregnancy ≥37 weeks and before the onset of labor from September 2020 to September 2021 were divided into a training set and a temporal validation set. Transperineal ultrasound was performed to collect angle of progression, head-perineum distance, subpubic arch angle, and their levator hiatal dimensions. The cervical length was measured via transvaginal ultrasound. The delivery methods were later recorded. Through LASSO regression analysis, indicators that can affect SVD failure were selected. Seven common machine learning algorithms were selected for model training, and the optimal algorithm was selected based on the area under the curve (AUC) to evaluate the effectiveness of the validation model.
RESULTS: Four indicators related to SVD failure were identified through LASSO regression screening: angle of progression, cervical length, subpubic arch angle, and estimated fetal weight. The Gaussian NB algorithm was found to yield the highest AUC (0.82, 95% confidence interval [CI] 0.65-0.98) during model training, and hence it was chosen for verification with the temporal validation set, in which an AUC of 0.79 (95% CI 0.64-0.95) was obtained with accuracy, sensitivity, and specificity rates of 80.9%, 72.7%, and 75.0%, respectively.
CONCLUSION: The Gaussian NB model showed good predictive effect, proving its potential as a clinical reference for predicting SVD failure of term nulliparous women before actual delivery.
PURPOSE: The purpose of this study was to examine the relationships between symptom burden and sleep problems and the role of depressive symptoms on these relationships in middle-aged and older adults with type 2 diabetes.
METHODS: The study employed a cross-sectional, correlational design with secondary analysis. De-identified data sets from three original studies were combined. A total of 189 men and women with type 2 diabetes were recruited using convenience sampling in midwestern United States. Symptom burden, sleep impairment and sleep disturbance, depressive symptoms, demographics, and diabetes-related variables were assessed. The participants were grouped into glucose-controlled and -uncontrolled groups to examine a multigroup effect. Multigroup path analyses were conducted.
RESULTS: The results indicated that symptom burden had direct and indirect effects through depressive symptoms on sleep disturbance in the controlled group, whereas only a direct effect was found in the uncontrolled group. For sleep-related impairment, significant direct and indirect effects of symptom burden were found via depressive symptoms in both groups, and the strength of the effects on each path differed between the groups.
CONCLUSIONS: Diabetes symptom burden was associated with sleep disturbance and sleep-related impairment in middle-aged and older adults with diabetes. A different approach should be considered for sleep management according to their A1C levels, and depressive symptoms can be a therapeutic target to treat sleep problems in the population.
OBJECTIVES: Liver cirrhosis (LC) can be caused by obesity, alcohol consumption, viral infection, and autoimmune disease. Early diagnosis and management of LC is important for patient quality of life. Non-invasive diagnostic methods are useful for predicting the current status and mortality risk of LC. The purpose of this study is to identify relevant diagnostic factors measured in routine laboratory test of alcohol-related liver cirrhosis (ALC) patients.
METHODS: This study analyzed data from 127 patients with ALC, including their laboratory test results and clinical information, including coagulation parameters, hematologic parameters, and biochemical parameters. These data were used to compare the performance of the prediction models from three machine learning algorithms including K-nearest neighbor (KNN), support vector machine (SVM), and random forest (RF).
RESULTS: Higher Model for End-stage Liver Disease (MELD) score were associated with prothrombin time (PT) and D-dimer. Logistic and multiple linear regression analyses revealed significant factors predicting mortality in the MELD group. Machine learning approaches were used to predict death in ALC patients using some laboratory parameters associated with mortality. The prediction model based on SVM exhibited better prediction performance than others.
CONCLUSION: PT and D-dimer were the factors that were most strongly associated with 90-day mortality, and machine learning methods can create prediction models with good predictive power.
Enteral formulas that contain long-chain polyunsaturated fatty acids (PUFAs), e.g. arachidonic acid (AA) and docosahexaenoic acid (DHA) essentially free of cholesterol, and a process for making such enteral compositions are described. More particularly, the invention relates to methods for reducing the incidence of necrotizing enterocolitis by administering compositions which provide n-6 and n-3 long chain PUFAs; phospholipids and/or choline. Compositions from egg yolk lipids are presently preferred as they contain n-6 and n-3 long chain PUFAs and are predominantly in a phosphtidylcholine form. This is believed to provide a synergistic effect. Also disclosed is a process of making such a composition that provides improved organoleptic and stability properties.
Predicting therapy from gut compositional data is described herein. In an example, a system accesses gut compositional data including a taxonomic abundance, a taxonomic diversity, and/or an enterotype for a subject. The system generates a gut microbiome signature for a safety and an efficacy of a statin therapy for the subject by applying a classifier to the gut compositional data. The safety of the statin therapy is characterized by an insulin resistance of the subject and the efficacy of the statin therapy is characterized by a blood hydroxymethylglutarate level of the subject. The system determines a recommended therapy for the subject based on the gut microbiome signature and one or more taxa of the gut compositional data of the subject. The recommended therapy is selected from a statin therapy intensity, a probiotic therapy, a prebiotic therapy, or a combination thereof. The system outputs the recommended therapy.
The invention provides a preparation that treats cancer, improves immunity and has hydrophilic or oleophilic ganodermataceae compound ingredients, which comprises an oleophilic glossy ganoderma spore oil and hydrophilic ganoderma polyhexose. The preparation can be made into emusion, lipidsome, inclusion compound formulation, nanometer grain and the prosoma formulation of the previous formulations. Wherein, the oleophilic ingredients are distributed in an oil phase or the inclusion compound; the hydrophilic ingredients are distributed in an external water phase, a surfactant or an internal water phase that is wrapped by the surfactant. The total drug-loading rate of the invention reaches 0.1 to 300mg/mL with a grain size of 0.01 to 100 Mu m and pH value of 6.0 to 9.0. With high drug-loading rate, the invention is able to reduce the toxic or side effects, ensure stable quality, convenient application, express and convenient preparation technique. Therefore, the invention can be applied for large quantity preparation and industrialized production.
Eligible Black Women's Health Study (BWHS) participants who completed the Insomnia Severity Index(ISI) on the 2015 BWHS questionnaire with a score compatible with insomnia disorder will be randomly selected to receive information that will inform them of the opportunity to participate in a free program designed to address their sleep problems. They will then be directed to an Insomnia Study Website which will provide information about the study and directions on how to complete an online screening questionnaire for those interested in participating. Reminders will be sent to these selected women to encourage participation.

Once interested women submit the screening questionnaire, an internal assessment will be carried out to see if potential participants are eligible. Those determined to be ineligible will be sent a thank you letter and informed that they were not selected for this trial. Those who meet the qualifications for the study will be directed to the informed consent form with a note indicating that a member of the study team will call them within several days at a time they indicated would be convenient for them. The study team member will then call each eligible subject and review with her, over the phone, each section of the consent form. A verbal acknowledgement of consent, or non-consent, will be recorded in the study database.

Once women have been verbally consented, they will be instructed on the use of the web programs and, completion of online sleep logs. Privacy concerns will be addressed. Pre-intervention, post-intervention, and 6-month assessment questionnaires, including the Insomnia Severity Index (ISI) will be administered pre-intervention (Time 1), post-intervention 9 weeks after Time 1 (Time 2), and 6 months later (Time 3). After the pre-intervention questionnaires and sleep logs are completed, participants will be informed of their treatment which was selected at random from the three online treatments: SHUTi -BWHS, SHUTi, and patient education (PE) (also called sleep hygiene or sleep information). The PE group will use a website that discusses ways to improve behaviors and environments that can affect sleep. This material is also included in the other 2 treatments but is presented in a different way. Participants using the PE website may log in as often as they like for as long as they like. Participants randomized to SHUTi-BWHS or SHUTi will use a web program that has six modules called Cores. Participants will log in to the six modules of their assigned treatment program over an 8-week period. Cores are completed one at a time in order. Each Core is expected to take 45 to 60 minutes to complete. Each Core contains information and exercises designed to help change behaviors and thoughts that can contribute to sleep problems.

Nine weeks after completing the initial pre-intervention questionnaire, all participants will be asked to complete another questionnaire about their sleep and health, which includes the ISI, and also to complete 10 sleep diaries. Six months later, participants will be asked again to complete a questionnaire that includes the ISI, followed by completion of 10 sleep diaries.
Phytophthora infestans is a major oomycete plant pathogen, responsible for potato late blight, which led to the Irish Potato Famine from 1845-1852. Since then, potatoes resistant to this disease have been bred and deployed worldwide. Their resistance (R) genes recognize pathogen effectors responsible for virulence and then induce a plant response stopping disease progression. However, most deployed R genes are quickly overcome by the pathogen. We use targeted sequencing of effector and R genes on herbarium specimens to examine the joint evolution in both P. infestans and potato from 1845-1954. Currently relevant effectors are historically present in P. infestans, but with alternative alleles compared to modern reference genomes. The historic FAM-1 lineage has the virulent Avr1 allele and the ability to break the R1 resistance gene before breeders deployed it in potato. The FAM-1 lineage is diploid, but later, triploid US-1 lineages appear. We show that pathogen virulence genes and host resistance genes have undergone significant changes since the Famine, from both natural and artificial selection.
A system for smart weighting detection are provided. The smart weighting detection system includes a server and a smart weighing device. Multiple weight values of the containing device detected by the smart weighing device are transmitted to the server. The server determines whether the change in liquid circulation of the containing is normal based on multiple weight values of the containing device. The normal change of the liquid circulation of the container that the change trend of the weight difference between the two weight values of the container obtained by the server at two adjacent times meets a normal condition. Abnormal changes in the liquid circulation of the container means that the changing trend of the weight difference between the two weight values of the container obtained by the server at two adjacent times does not meet normal conditions.
PROBLEM TO BE SOLVED: To decrease the jobs of staffs by outputting the control information on the patients corresponding to the types of jobs of the staff respectively in the form of a log via the designation of job log output of every staff. SOLUTION: The input terminals 101 and 102 input the information on the disease conditions and nursing situations and the information on the staff, and a management device 103 manages these information. A management information input means 108 registers the management information 110 such as the staff information 105 including the job types, the duty systems, etc., of staffs and inputted via a terminal, the case information 106, etc. A log editing output means 109 automatically outputs the corresponding item to a nurse log 111 in the form of a log based on various registered management information when a log output instruction is received. Thus, the management information on the disease/nursing situations of patients of the staff as well as the job types of staffs are registered in response to each job type.  When the job log output is designated for every staff, the management information on the patient corresponding to the job type of every set staff is outputted as a log.
Suicide is one of the worldwide leading causes of unnatural death. Pretoria is a capital city of South Africa and is the fourth most populated city in South Africa. Between 16 and 22 suicide cases are recorded daily in South Africa.Case files from the Pretoria Medico-Legal Laboratory were reviewed between 1 January 2015 to 31 December 2021, which spanned the COVID-19 pandemic. All cases of possible and probable suicides were included. One-way analysis of variance and Pearson chi 2 tests were conducted to determine statistical significance in the observed trends.A total of 1820 possible and probable suicide cases were identified. The year following the outbreak of the COVID-19 pandemic accounted for the largest number of suicides. White males were the most heavily represented population, followed by Black males. Hanging was the most common method for males, whereas poisoning via ingestion and/or overdose was more commonly used by females.Suicides in Pretoria have increased since previous studies from 9.74% and 10.2% to 13.32%. Methods used have changed among various population groups over the past two decades. This paper examined changes in suicide trends in Pretoria compared to previous studies and highlighted correlations between suicide trends and COVID-19 lockdown measures.